StockData

Eton Pharmaceuticals vs Protalix BioTherapeutics

ETON and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ETON and PLX compare

Eton Pharmaceuticals is the larger company, worth 7.5 times as much as Protalix BioTherapeutics ($1.8B against $244M).

On earnings, Protalix BioTherapeutics is cheaper: it trades at 13.2× trailing earnings, against 164× for Eton Pharmaceuticals.

Eton Pharmaceuticals grew revenue faster over the last twelve months (81.5% versus 30.1% for Protalix BioTherapeutics).

Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 23.5% compared with 12.0% at Eton Pharmaceuticals.

Protalix BioTherapeutics scores higher on the StockData Score (16 against 10 for Eton Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricETONPLX
Size and price
Market cap$1.8B$244M
Share price$63.88$3.03
Change, 1 year278%57.0%
Change, 5 years1414%206%
Beta (5Y)−0.441.33
Employees44226
StockData Score
Total score1016 (better)
Valuation score04 (better)
Growth score3 (better)2
Performance score44
Health score36 (better)
Dividend score00
Valuation
P/E164×13.2× (better)
P/S17.3×3.0× (better)
P/B39.2×3.4× (better)
EV/EBITDA87.6×9.3× (better)
P/FCF124×31.8× (better)
FCF yield0.81%3.1% (better)
Fair value$10.29$5.40
Margin of safety−521%43.9% (better)
Growth
Revenue growth (TTM)81.5% (better)30.1%
Revenue growth, 5Y average360% (better)−3.5%
Net income growth (TTM)–202%
EPS growth (TTM)–475%
Profitability
Gross margin57.9%69.2% (better)
Operating margin15.4%28.9% (better)
Net margin12.0%23.5% (better)
FCF margin14.0% (better)9.5%
Return on equity36.0% (better)31.2%
Return on invested capital42.5%49.5% (better)
Financial health
Debt / equity0.60 (better)0.00
Net debt / EBITDA0.05–
Interest coverage3.6×–
Current ratio1.522.94 (better)
Altman Z-score16.25 (better)5.85
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions74.0%17.9%
Held by insiders5.6%3.8%
Insider net buying, 12 months−$35.0M$101K (better)
Short interest, % of float7.4%4.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.